Bezlotoxumab is a human monoclonal antibody that binds with high affinity to C. difficile toxin B and neutralises its activity. CDI recurrence is prevented through the provision of passive immunity against toxin produced by the outgrowth of persistent or newly-acquired C. difficile spores.
The efficacy of bezlotoxumab was evaluated in the MODIFY I and II clinical trials – please see the link below for details.